Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation

Philippe, D.; Chakass, D.; Thuru, X.; Zerbib, P.; Tsicopoulos, A.; Geboes, K.; Bulois, P.; Breisse, M.; Vorng, H.; Gay, J.; Colombel, J.-F.; Desreumaux, P.; Chamaillard, M.
June 2006
Gut;Jun2006, Vol. 55 Issue 6, p815
Academic Journal
Background and aims: Recent studies with μ opioid receptor (MOR) deficient mice support a physiological anti-inflammatory effect of MOR at the colon interface. To better understand the potential pharmacological effect of certain opiates in inflammatory bowel diseases (IBD), we (1) evaluated the regulation in vivo and in vitro of human MOR expression by inflammation; and (2) tested the potential anti-inflammatory function of a specific opiate (DALDA) in inflamed and resting human mucosa. Patients and methods: Expression of MOR mRNA and protein was evaluated in healthy and inflamed small bowel and colonic tissues, isolated peripheral blood mononuclear cells and purified monocytes, and CD4+ and CD8+ T cells from healthy donors and IBD patients. The effect of cytokines and nuclear factor κB (NFκB) activation on MOR expression in lymphocyte T and monocytic human cell lines was assessed. Finally, DALDA induced anti-inflammatory effect was investigated in mucosal explants from controls and IBD patients. Results: MOR was expressed in ileal and colonic enteric neurones as well as in immunocytes such as myeloid cells and CD4+ and CD8+ T cells. Overexpressed in active IBD mucosa, MOR was significantly enhanced by cytokines and repressed by NFκB inhibitor in myeloid and lymphocytic cell lines. Furthermore, ex vivo DALDA treatment dampened tumour necrosis factor α mRNA expression in the colon of active IBD patients. Conclusions: Given the increased expression of MOR and the ex vivo beneficial effect of DALDA in active IBD, natural and/or synthetic opioid agonists could help to prevent overt pathological intestinal inflammation.


Related Articles

  • The Pro-inflammatory Cytokines, IL-1 β and TNF- α, Inhibit Intestinal Alkaline Phosphatase Gene Expression. Malo, Madhu S.; Biswas, Shaluk; Abedrapo, Mario A.; Yeh, Lisa; Chen, Alexander; Hodin, Richard A. // DNA & Cell Biology;Dec2006, Vol. 25 Issue 12, p684 

    High levels of the pro-inflammatory cytokines, interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α), are present in the gut mucosa of patients suffering form various diseases, most notably inflammatory bowel diseases (IBD). Since the inflammatory milieu can cause important...

  • Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP. Salari, Pooneh; Abdollahi, Mohammad // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jan2009, Vol. 3 Issue 1, p69 

    Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two chronic intestinal diseases having a mutual pathophysiological pathways with different manifestations. Generally, inflammatory mediators and cytokines orchestrate the scenario that amongst them, tumor necrosis...

  • Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Wiegering, V.; Morbach, H.; Dick, A.; Girschick, H. J. // Rheumatology International;Apr2010, Vol. 30 Issue 6, p801 

    Tumor necrosis factor alpha (TNFα) has broad effects on the immune system including lymphoid organ development as well as growth, survival und function of immune cells. TNFα has two main functions: regulatory effects and proinflammatory activities. In several diseases such as juvenile and...

  • Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Balding, Joanna; Livingstone, Wendy J.; Conroy, Judith; Mynett-Johnson, Lesley; Weir, Donald G.; Mahmud, Nasir; Smith, Owen P. // Mediators of Inflammation;Jun2004, Vol. 13 Issue 3, p181 

    T he mechanisms responsible for development of inflammatory bowel disease (IBD) have not been fully elucidated, although the main cause of disease pathology is attributed to up-regulated inflammatory processes. The aim of this study was to investigate frequencies of polymorphisms in genes...

  • Maintenance of Remission in Crohn’s Disease: Current and Emerging Therapeutic Options. Brookes, Matthew J.; Green, Jonathon R.B. // Drugs;2004, Vol. 64 Issue 10, p1069 

    Crohn's disease is a chronic inflammatory bowel disorder with a relapsing and remitting course. Once remission is achieved, the main aim of the management of Crohn's disease is maintenance of that remission. Significant advances have been made into understanding the aetiology and pathogenesis of...

  • The classics in perspective. Panés, Julián; Ghosh, Subrata // Gut;Sep2007, Vol. 56 Issue 9, p1184 

    The authors reflect on the development of anti-cytokine therapies as biological agents in treating Crohn's disease and inflammatory diseases. Their therapeutic approach to these diseases has expanded. They noted that gastroenterologists face a remarkable wave of new biological therapies for...

  • CORRECTION.  // Gut;Nov2004, Vol. 53 Issue 11, p1722 

    Several corrections to the articles including "Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor antibody treatment," by S. J. Connor, "Morphological characterisation of Crohn's disease fistulae," by F. Bataille, and "Divergent patterns...

  • Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients. Ohama, Takashi; Hori, Masatoshi; Fujisawa, Masahiko; Kiyosue, Masaharu; Hashimoto, Masaki; Ikenoue, Yuka; Jinno, Yoshio; Miwa, Hiroto; Matsumoto, Takayuki; Murata, Takahisa; Ozaki, Hiroshi // Journal of Gastroenterology;2008, Vol. 43 Issue 11, p858 

    Chronic intestinal inflammation is frequently accompanied by motility disorders. We previously reported that proinflammatory cytokines, such as tumor necrosis factor α and interleukin (IL)-1β downregulate CPI-17, an endogenous inhibitor of serine/threonine protein phosphatase in...

  • Biologic response modifiers to decrease inflammation: Focus on infection risks. Saux, Nicole Le // Paediatrics & Child Health (1205-7088);Mar2012, Vol. 17 Issue 3, p147 

    Biologic response modifiers are a novel class of drugs used by sub-specialists to treat immune-mediated conditions such as juvenile idiopathic arthritis and inflammatory bowel disease. Also known as 'cytokine inhibitors', they are proteins whose purpose is to block the action of cytokines...


Read the Article


Sign out of this library

Other Topics